Hazardous Drug Detection for Employee Safety

RG+A was engaged by a global device manufacturer to help determine market response to a potential new device for testing for the presence of trace hazardous drugs in hospital pharmacies and infusion areas. The client sought to determine whether to continue development of the product and in what form.

View Case Study

Assessing Market Potential and Development Strategy

RG+A was engaged by a diagnostics manufacturer to help determine the best business approach to for a potentially disruptive prostate cancer screening product – continue development, sell the asset, or discontinue. RG+A conducted telephone-based mini-groups among key stakeholders, and incorporated the findings into a Monte Carlo model to determine the likelihood of achieving the client’s threshold for revenue success.

View Case Study

Using DPS®/Conjoint to Formulate a Competitive Response

The contraception franchise of a major pharmaceutical company was under competitive threat by a discount product coming to market within two years. RG+A was engaged to help the client understand the impact to their franchise – both inline and pipeline products – and to identify variations of the competitor’s product profile that would have the greatest impact on share.

View Case Study

Generic Competition Assessment Among Payers Using PV Scope®

Facing imminent generic competition for their branded respiratory product, a pharmaceutical company engaged RG+A to help them understand the complex payer stakeholder landscape and to provide guidance on key strategies to strengthen the brand’s position with payers at present and following the generic launch

View Case Study

Using Co-Creation with Payers to Support Optimal Product Profile Development and Clinical Trial Design

RG+A’s client sought to optimize the post-launch value of their early stage respiratory asset by incorporating key payer perspectives into product strategy and trial design in support of high likelihood of reimbursement. RG+A used our Co-Creation approach to engage payers from our Health Payer Council community directly in the development of an optimal target product profile (TPP) and viable trial design to support the client’s post-launch objectives.

View Case Study

Forecasting for Multiple Indications within the ADHD Market

RG+A’s client needed to make a go/no-go decision for a Phase III clinical trial for a novel ADHD medication. It was unknown whether or not the product would get either an adult or adult and pediatric indication. RG+A used a combination of DPS® and QTM® methodologies to deliver answers to all of these major research questions along with a recommendation about how to proceed with the Phase III clinical trial.

View Case Study